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Minocycline, a tetracycline-class of antibiotic, has been tested with mixed effectiveness
on neuromuscular disorders such as amyotrophic lateral sclerosis, autoimmune neuritis
and muscular dystrophy. The independent effect of minocycline on skeletal muscle force
production and signalling remain poorly understood. Our aim here is to investigate
the effects of minocycline on muscle mass, force production, myosin heavy chain
abundance and protein synthesis. Mice were injected with minocycline (40 mg/kg i.p.)
daily for 5 days and sacrificed at day six. Fast-twitch EDL, TA muscles and slow-
twitch soleus muscles were dissected out, the TA muscle was snap-frozen and the
remaining muscles were attached to force transducer whilst maintained in an organ
bath. In C2C12 myotubes, minocycline was applied to the media at a final concentration
of 10 µg/mL for 48 h. In minocycline treated mice absolute maximal force was lower
in fast-twitch EDL while in slow-twitch soleus there was an increase in the time to
peak and relaxation of the twitch. There was no effect of minocycline treatment on
the other contractile parameters measured in isolated fast- and slow-twitch muscles.
In C2C12 cultured cells, minocycline treatment significantly reduced both myosin heavy
chain content and protein synthesis without visible changes to myotube morphology. In
the TA muscle there was no significant changes in myosin heavy chain content. These
results indicate that high dose minocycline treatment can cause a reduction in maximal
isometric force production and mass in fast-twitch EDL and impair protein synthesis
during myogenesis in C2C12 cultured cells. These findings have important implications
for future studies investigating the efficacy of minocycline treatment in neuromuscular or
other muscle-atrophy inducing conditions.
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INTRODUCTION
Minocycline is part of the tetracycline family of broad-spectrum
antibiotics. In addition to the well-established antibacterial
clinical uses of minocycline, it has gained interest as a possible
treatment for neuromuscular disorders, in part because of its
improved lipid solubility and uptake into cerebrospinal fluid
compared to other tetracyclines (Richards et al., 1981; Orsucci
et al., 2009). The mechanisms of tetracycline action in neural
and neuromuscular disorders have typically been focused on
its anti-apoptotic properties, particularly through mitochondria
(Orsucci et al., 2009, 2012; Griffin et al., 2011). While many
studies have reported the potential benefit of minocycline
treatment in neuromuscular conditions such as amyotrophic
lateral sclerosis (Kriz et al., 2002), neuropathies and muscular
dystrophies (Orsucci et al., 2012), there is evidence that in
some instances minocycline treatment may have detrimental
clinical outcomes or physiological outcomes; for example, despite
promising findings in animal studies, a phase III clinical trial
of minocycline in ALS patients found it worsened clinical
deterioration (Gordon et al., 2007). In a clinical case-study,
Bokuda et al. (2012) reported skeletal muscle pigmentation,
autophagic vacuoles, and scattered atrophic fibres in a 75-year-
old patient who had been prescribed minocycline for several
years. In C. elegans, minocycline treatment increased lifespan,
however, it reduced protein synthesis rate (Solis et al., 2018),
consistent with findings in minocycline-treated cancer cells
(Jung et al., 2014).
Given the skeletal muscle atrophy which occurs in
many neuropathies and neuromuscular conditions is
often accompanied by sarcopenia in older populations, the
independent effects of minocycline on skeletal muscle function
needs to be considered. Specifically, whether there are any
selective actions on different fibre types, focusing on fast-
twitch fibres known to be susceptible to atrophy in sarcopenia
(Deschenes, 2004; Narici and Maffulli, 2010; Picard et al., 2011;
Schiaffino and Reggiani, 2011). The effect of tetracyclines,
particularly minocycline, is poorly understood in reference
to skeletal muscle function and atrophy. Oral minocycline
treatment improved grip strength, but not muscle mass in
response to cancer cachexia in mice despite reducing neural
inflammation (Norden et al., 2015), and tetracycline injection
did not prevent atrophy caused by external fixation, a form of
limb immobilisation, despite improving expression of myogenic
proteins (Shefer et al., 2008). In contrast, Obradović et al.
(2016) reported hypertrophy with tetracycline treatment in
cultured skeletal muscle, and in a mouse model of muscular
dystrophy type 1A either minocycline or doxycycline treatment
enhanced lifespan, and doxycycline treatment reduced the
severity of muscle atrophy (Girgenrath et al., 2009). However,
in this study they were not able to identify whether the
mechanism of protection was neural or myogenic. Because
of the contradictory reports in the literature investigating
tetracyclines and minocycline as an anti-atrophic agent, this
study aimed to investigate the effects of minocycline on skeletal
muscle contractile function, size, and protein synthesis using a
combination of animal and cell culture methodologies.
MATERIALS AND METHODS
Ethics Approval
Research and animal care procedures were approved by the
Western Sydney University Animal Ethics Committee A11938
in accordance with the Australian Code of Practice for the Care
and Use of Animals for Scientific Purposes as laid out by the
National Health and Medical Research Council of Australia.
These experiments were conducted in compliance with the
animal ethics checklist and ethical principles under which the
journal operates.
Animals and Treatment
Weaned (3-week-old) male C57Bl/6 mice (n = 10) were
purchased from the Animal Resources Centre, Murdoc, WA,
Australia1 and acclimatised for 1 week to adapt in new
environment prior to start injection. Mice were housed
(maximum of 3 mice per cage) in ventilated GM500 cages
(Tecniplast, Buguggiate, VA, Italy) in the local animal care facility
(School of Medicine, Western Sydney University). Standard
rodent pellet chow (Gordon’s Specialty Stockfeeds, Yanderra,
NSW, Australia) and water were available ad libitum. Basic
enrichments such as nesting crinkle material and polyvinyl
chloride pipe tube were provided. Mice were maintained in
a temperature controlled environment throughout the entire
period as previously described (Sen et al., 2019). At 4 weeks
of age, mice (n = 5) were injected with 40 mg/kg Minocycline
(Sigma-Aldrich, St Lucia, MO, United States dissolved in distilled
water) intraperitoneally (29G syringe, erumo, Elkton, MD,
United States) each day for five days at a similar time (10–11
am). No placebo or saline injections were used for control mice
(n = 5). Mice were weighed every day to monitor general health.
No abnormality in body condition, posture and injury were found
following injections. On the 6th day mice were overdosed using
intraperitoneal sodium pentabarbitone injection (250 mg/kg,
LethobarbTM, Tory laboratories, Glendenning, NSW, Australia).
Muscle Preparation
The fast-twitch Tibialis anterior (TA), fast-twitch Extensor
digitorum longus (EDL) and slow-twitch Soleus muscles were
dissected from the hind limb. TA muscles were immediately
snap-frozen while EDL and soleus muscles were tied by the
tendons from one end to a dual force transducer/linear tissue
puller (300 Muscle Lever; Aurora Scientific Instruments, ON,
Canada) and secured to a base at the other end using 6-
0 silk sutures (Pearsalls, Somerset, United Kingdom). During
preparation and contractile protocols, the muscles were kept
in a dissection/organ bath containing Krebs solution with
composition (in mM): 4.75 KCl, 118 NaCl, 1.18 KH2PO4, 1.18
MgSO4, 24.8 NaHCO3, 2.5 CaCl2 and 10 glucose, 0.1% fetal
calf serum, 1 drop antifoam A (BioChemika, Sigma-Aldrich)
and bubbled continuously with carbogen to maintain pH at
7.4. As experiments were performed on one setup, the fast-
twitch EDL muscle was mounted first whilst the slow-twitch
1www.arc.wa.gov.au
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soleus is pinned out on a dissection dish and submerged in
bubbling Krebs solution.
The muscle was stimulated by delivering a current between
two parallel platinum electrodes, using an electrical stimulator
(701C stimulator; Aurora Scientific Instruments). All contractile
procedures were designed, measured, and analysed using the
615A Dynamic Muscle Control and Analysis software (DMC
version 5.417 and DMA version 5.201; Aurora Scientific
Instruments). At the start of the experiment, the muscle was
set to optimal length (Lo), which will produce maximal twitch
force, and measured. These experiments were conducted blinded
to treatment, contractile protocols and dissection were at a room
temperature of∼20–22◦C.
Initial Maximum Force
The initial supramaximal stimulus was given at 1 ms, 125 Hz for
1 s, and force produced was recorded as Po, the maximum force
output of the muscle at Lo.
Force Frequency Curve and Twitch
Kinetics
Force-frequency curves were generated before fatigue and after
recovery to measure muscle contractile function. Trains of
stimuli given at 1 ms at different frequencies, including 2, 15,
25, 37.5, 50, 75, 100, and 125 Hz for 1 s for fast-twitch EDL
and 2 s for slow-twitch soleus and the force produced was
measured. A 30-s rest occurred between each frequency. At 2 Hz
stimulation frequency (where individual twitches are observed)
the following twitch kinetics parameters were collected: twitch
force, half relaxation time (HRT) and time to peak (TTP).
A sigmoid curve relating the muscle force (P) to the
stimulation frequency (f) was fitted by linear regression to
this data.
The curve had the equation:







From the fitted parameters of the curve, the following contractile
properties were obtained: force developed at minimal (Pmin)
and maximal (Pmax) stimulation at the conclusion of the force-
frequency curve. Half-frequency (Kf) is the frequency at which
the force developed is halfway between (Pmin) and (Pmax), and
Hill coefficient (h) which provides a way to quantify the calcium
binding affinity of the muscle during contraction. These were
used for population statistics.
Fatigue and Recovery
To test the rate of fatigue development, trains of contraction
stimuli were given at 1 ms, 125 Hz for 1 s for fast-twitch EDL
and 1 ms, 100 Hz for 2 s for slow-twitch soleus. For fatigue
development a total of 15 maximal isometric contractions were
given with 1 s break after each stimuli, upon completion muscle
recovery was measured by delivering the same stimuli at 30 s,
1, 3, 5, 7, 9, 11, 13, and 15 min respectively. Force values were
expressed as a percentage of first fatigue contraction.
Length Mass and Physiological CSA
Whole muscle length was measured using vernier muscle calipers
while sitting at optimal length within the organ bath. All
muscles were blotted dry (Whatmans filter paper DE81 grade)
and weighed using an analytical balance (GR Series analytical
electronic balance) following contractile procedures. Forces were
normalised with respect to an estimate of physiological cross-
sectional area, according to the equation CSA = MM/(Lo∗D)
(Hayes and Williams, 1998), where MM is the muscle mass, Lo
is the optimal length, and D is the density of skeletal muscle
(1.06 g/cm3), to enable comparisons between muscles of differing
sizes and weights.
Cell Culture and Treatment
C2C12 myoblasts, a mouse derived skeletal muscle cell
culture, were obtained from American Type Culture Collection
(Manassas, VA, United States) and grown in Dulbecco’s
Modified Eagle Medium (DMEM; Sigma-Aldrich, St. Louis, MO,
United States) containing 4.5 g/L glucose and supplemented
with 10% fetal bovine serum (Bovogen Biologicals, Melbourne,
VIC, Australia) and antibiotics (1% of final media volume
consisting of 100 U/mL penicillin and 100 µg/mL streptomycin;
Sigma-Aldrich). At 90–95% confluence, cells were induced to
differentiate into myotubes by replacing the growth media
with DMEM containing 4.5 g/L glucose plus 2% horse serum
(Sigma-Aldrich) and antibiotics for 3 days before initiating
experimental treatments. Minocycline (Sigma-Aldrich), was
diluted in DMEM at a final concentration of 10 µg/ml before
being added to the treatment media for 48 h to observe
direct effects. This concentration is similar to other studies
investigating the effects of tetracycline in cultured skeletal muscle
(Obradović et al., 2016).
Tissue Sample Preparation and Western
Blot Analysis
Whole cell lysates were prepared using a RIPA buffer
(Sigma-Aldrich), sonicated, and cleared of cellular debris
by centrifugation at 14,000g for 15 min. TA muscles were snap-
frozen in liquid nitrogen and homogenised with RIPA buffer
(Sigma-Aldrich) using a DUALL Tissue Homogeniser (Kimble
Kontes). Tissue was centrifuged at 3,000g for 10 min, and
then 14,000g for 15 min prior to measuring concentrations of
protein in the lysates using the Bradford Protein Assay (Thermo
Fisher Scientific, Waltham, MA, United States). Western blot
analyses were performed as described previously (Gao et al.,
2008) using nitrocellulose membranes (Biorad; Hercules, CA,
United States) and commercial antibodies to Myosin (Merck,
Darmstadt, Germany). Equal protein loading and electroblot
transfer were verified by staining the membrane post transfer
with Ponceau S Red (Sigma-Aldrich). This method has been
routinely used (Perry et al., 2018) and validated as a reliable
measure of protein loading with immunoblotting (Romero-
Calvo et al., 2010). Following application of Chemiluminescent
Substrate (SuperSignalTM West Pico PLUS, Thermo Fisher),
densities of detected protein bands were recorded with a
BioRad chemiluminescence imager (ChemiDoc XRS+, BioRad)
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and densities determined using Image J (NIH, Bethesda,
MD, United States).
Protein Synthesis Assay (SUnSET)
Protein synthesis was measured using the SUrface SEnsing of
Translation (SUnSET) method which measures the incorporation
of puromycin into nascent peptide chains (Schmidt et al., 2009;
Goodman et al., 2011). Puromycin dihydrochloride (Sigma-
Aldrich) was added to the cell treatment media (1 µM final
concentration) for 30 min prior to cell lysis with a standard
RIPA buffer. Twenty micrograms of protein were separated
in a 10% polyacylamide gel until the dye-front was ∼2 cm
from the bottom of the gel. Proteins were transferred to
nitrocellulose membranes (BioRad) and subsequently incubated
in TBST buffer containing 5% skim milk powder and incubated
overnight with a monoclonal puromycin antibody (clone 12D10,
EMD Millipore, Temecula, CA, United States, diluted 1:5000
in TBST). Membranes were then incubated for 1 h in TBST
containing 5% skim milk plus a secondary mouse antibody
(Sigma-Aldrich, 1:10000). The total lane density was analysed
using Image J (NIH).
Statistical Analyses
Data was presented as means and standard deviation (±SD).
For all data from whole mouse muscle, measurements were
analysed via student unpaired t-tests when comparisons were
made between two groups. Unpaired t tests were used when
comparisons were made between conditions with protein
synthesis and myosin protein abundance in the C2C12 myotubes.
Results were considered statistically significant at p < 0.05, but
data where the p-value was under <0.15 were presented in
text with 95% confidence intervals for greater statistical insight
and clarity into the results. All statistical tests and curve fitting
were performed using a statistical software package Prism 7
(GraphPad, CA, United States).
RESULTS
Muscle Length, Mass and Physiological
CSA
In the fast-twitch EDL muscle, minocycline treatment reduced
the mass of the muscle by 8%, and although not statistically
significant (MD −1,09, 95% CI [−2.417, 0.2372], P = 0.102),
the distribution of the 95% confidence intervals and proximity
to statistical significance strongly suggests the EDL mass was
lowered with minocycline treatment, while in the slow-twitch
soleus muscle the mass was unaffected by minocycline treatment
(Table 1). In both the fast-twitch EDL and slow-twitch soleus,
there were no significant differences in muscle length between
control and minocycline-treated mice. When physiological cross-
sectional area was calculated from these two parameters, a similar,
but not significant reduction in PCSA can be seen in minocycline
treated EDL muscle (MD −0.089, 95% CI [−0.2143, 0.03608],
P = 0.13). No significant differences in physiological cross-
sectional area was seen in soleus muscle.
Twitch Kinetics and Force
The twitch characteristics of the fast-twitch EDL and slow-
twitch soleus muscles, including time to peak, half relaxation
time and twitch force (absolute and specific force corrected
to muscle CSA) are shown in Table 2. In the fast-twitch EDL,
none of the recorded twitch characteristics were significantly
different in the minocycline treated group compared to
TABLE 1 | Statistical analyses and sample size for muscle mass, length and physiological cross-sectional area (PCSA) of fast-twitch EDL and slow-twitch soleus
muscles for control and minocycline treated groups.
EDL Soleus
Control Minocycline P-value Control Minocycline P-value
Muscle mass (mg) 14.1 ± 1.0 13.0 ± 1.7 0.102 11.2 ± 0.7 11.5 ± 2.3 NS
Muscle length (mm) 13.2 ± 0.3 13.2 ± 0.3 NS 11.5 ± 0 11.5 ± 0 NS
PCSA (mm2) 1.01 ± 0.07 0.93 ± 0.1 0.13 0.92 ± 0.06 0.94 ± 0.2 NS
Sample size (muscles) 10 10 10 10
Values are means ± SD. NS: not significant via unpaired t-test.
TABLE 2 | Statistical analyses and sample size of single twitch kinetics for fast-twitch EDL and slow-twitch soleus muscles for control and minocycline treated groups.
EDL Soleus
Control Minocycline P-value Control Minocycline P-value
Time to peak (ms) 29.4 ± 2.7 30.6 ± 2.7 NS 59.5 ± 8.9 69.6 ± 9.2* 0.026
Half relaxation time (ms) 14.6 ± 3.2 14.9 ± 2.3 NS 90.6 ± 18.6 117.3 ± 31.6* 0.037
Twitch absolute force (mN) 60.0 ± 7.2 60.4 ± 8.6 NS 31.5 ± 10.3 36.2 ± 10.6 NS
Twitch specific force (mN/mm2) 59.8 ± 9.0 66.3 ± 9.7 NS 34.4 ± 11.1 39.5 ± 13.1 NS
Sample size (muscles) 7 9 10 9
Values are means ± SD. *P < 0.05. NS: not significant via unpaired t-test.
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controls. In the slow-twitch soleus, both the time to reach peak
twitch force (MD 10.11, 95% CI [1.338, 18.88], P = 0.026)
and half relaxation time (MD 26.63, 95% CI [1.822, 51.43],
P = 0.0369) were significantly increased by minocycline
treatment. Absolute and specific twitch force were not
statistically different between control and minocycline-treated
mice (Table 2).
Force Frequency Curves and Maximum
Force
Fast-twitch EDL muscle treated with minocycline produced 12%
less maximum force (MD −55.16, 95% CI [−105.7, −4.632],
P = 0.035) compared to untreated controls (Figures 1A,C). All
other force frequency parameters measured in EDL muscles
were not altered by minocycline treatment (Figures 1B,D–H).
In the slow-twitch soleus there were no statistical differences
in either absolute or specific maximum force, half frequency
or Hill coefficient between the control and minocycline-treated
mice (Figure 2).
Muscle Fatigability
The decline in force during the fatiguing protocol and force
recovery were not significantly different between the control and
minocycline conditions in either the fast-twitch EDL (Figure 3A)
or slow-twitch soleus (Figure 3B) muscles.
Protein Synthesis and Myosin Protein
Abundance
Minocycline treatment for 48 h in cultured C2C12 myotubes
caused a 23% reduction (MD −2.577, 95% CI [−3.646, −1.508],
P = 0.0011) in protein synthesis, as measured by puromycin
incorporation (Figures 4A,B). Minocycline also caused a 70%
decline (MD −9.93, 95% CI [−13.44, −6.413], P = 0.0005) in
total myosin protein abundance in myotubes (Figures 4C,D),
however, a reduced effect that was not significantly different was
observed in TA muscles (Figures 4E,F). Despite the decline in
protein synthesis and reduction in myosin with minocycline,
the cells appeared morphologically similar, and the minocycline
treated cells did not show any visible signs of cell shrinkage and
apoptosis (Figures 4G,H).
DISCUSSION
In mice, five consecutive daily treatments of minocycline
intraperitoneal injection (40 mg/kg) lowered mass and absolute
maximal force production in fast-twitch EDL muscle, slowed
twitch rise and relaxation times in slow-twitch soleus muscle,
while having no effect on muscle mass in slow-twitch soleus
muscles. Furthermore, minocycline treatment in C2C12
myotubes reduced both protein synthesis and myosin heavy
chain content, however, myosin heavy chain content analysis of
the TA muscle showed no effect of minocycline treatment. These
results demonstrate that minocycline does not directly exert any
hypertrophic or functional improvements in healthy skeletal
muscle. These will be important considerations for future work
examining minocycline as a treatment for conditions which
exhibit muscle atrophy.
This study was the first to investigate the effects of minocycline
on isolated adult skeletal muscle contractile force properties,
including twitch kinetics, force frequency analysis and fatigability
testing. The most notable finding was the 12% decrease in
absolute EDL maximal force production (Figure 1). It is
noteworthy that this difference was not found when force was
expressed specific to muscle physiological CSA. This finding
indicates the decrease in EDL maximum force could be, in part,
related to a reduction in the amount of the fast-twitch contractile
protein myosin, which is reflected in the weight reduction
recorded in the EDL in response to minocycline. Whilst the
reduction in EDL mass was not statistically significant (<0.05),
the 95% confidence interval (MD−1.09, 95% CI[−2.417, 0.2372],
P = 0.102), combined with the ablation of the minocycline-
induced decrease in max force when EDL max force was
normalized to PCSA indicates that EDL mass was reduced with
minocycline treatment, and is also consistent with the findings
in C2C12 myotubes. In humans, and indeed in many animals,
limb skeletal muscles are comprised of a mixture of fast- and
slow-twitch fibres. The EDL and soleus mouse muscle are unusual
in that they are predominantly comprised of fast or slow-twitch
profile fibres (Augusto et al., 2004), respectively, which allows
us to differentiate the fibre type response to minocycline. More
specifically the mouse EDL is an mixture of approximately∼79%
type 2B (fast glycolytic), ∼16% type 2X and ∼4% type 2A (fast
oxidative glycolytic) muscle fibres while the soleus contains a
population of ∼39% type 2A, ∼30% type 1 (slow oxidative),
∼26% type 2X and 5% type 2B (Hettige et al., 2020). If the
minocycline is reducing the amount of fast 2B/X/A myosin
produced, then this would mean that the minocycline treated
soleus would contain a higher proportion of slow type 1 myosin
(as there was no change in mass) accounting for our finding of the
slowing of the twitch and relaxation. The slower time to peak and
relaxation in the soleus could be due to a shift toward a greater
amount of type 1 myosin or it may be due to an increased calcium
leak from the SR as a consequence of the lipid soluble minocycline
entering and concentrating within the muscle fibre.
The effects of minocycline treatment on mouse-derived
C2C12 myotubes were substantial. Forty-eight hours of
minocycline treatment reduced protein synthesis by 23%,
and substantially reduced total myosin heavy chain content
(Figure 4C). This decline in protein synthesis is comparable to
the degree of protein synthesis reduction found in minocycline
treated C. elegans and in minocycline treated cancer cells (Jung
et al., 2014; Solis et al., 2018). It is important to note that while
the minocycline-treated cells had far lower myosin heavy chain
abundance, they appeared visibly and morphologically identical
under low magnification (Figures 4G,H). This indicates despite
these substantial changes to myosin heavy chain content and
protein synthesis, there were no overt signs of cell death. Indeed,
minocycline treatment in C. elegans increased lifespan despite
a very similar decline in protein synthesis (Solis et al., 2018),
indicating despite the deleterious effects of minocycline on
myosin heavy chain content and protein synthesis, minocycline
may also have some undescribed protective function. However,
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FIGURE 1 | Force frequency characteristics of the fast-twitch EDL muscle expressed in absolute and specific (relative to muscle CSA) units from control (blue) and
minocycline (Mino; red) groups. (A,B) Force frequency curve from the EDL in absolute (A) and specific (B) units, which were not different with minocycline treatment.
(C,D) Lower EDL absolute maximal force in minocycline treated-mice (C), but not when expressed relative to muscle CSA (D). (E,F) EDL half frequency was not
different with minocycline treatment in either absolute (E) or specific (F) units. (G,H) EDL Hill coefficient was not different with minocycline treatment in either absolute
(G) or specific (H) units. n = 7 for Control, and n = 9 for Mino for all measures. *p < 0.05 via unpaired t-test. Values are mean ± SD.
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FIGURE 2 | Force frequency characteristics of the slow-twitch soleus muscle expressed in absolute and specific (relative to muscle CSA) units from control (blue)
and minocycline (Mino; red) groups. (A,B) Force frequency curve from the soleus in absolute (A) and specific (B) units, which were not different with minocycline
treatment. (C,D) soleus maximal force was not different with minocycline treatment either in absolute (C) or specific (D) units. (E,F) Soleus half frequency was not
different with minocycline treatment in either absolute (E) or specific (F) units. (G,H) Soleus Hill coefficient was not different with minocycline treatment in either
absolute (G) or specific (H) units. For all measurements, n = 10 for Control, and n = 9 for Mino. Values are mean ± SD.
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FIGURE 3 | Minocycline treatment does not alter fast-twitch EDL or slow-twitch soleus fatigability. (A) Fast-twitch EDL force decline during fatiguing stimulated
contractions or force recovery is not altered with minocycline treatment. (B) Slow-twitch soleus force decline during fatiguing stimulated contractions or recovery is
not altered with minocycline treatment. Statistical analysis was performed at fatigue end point t = 30 s and recovery end point t = 15 min (Table 3). EDL muscle:
n = 7 for Control, n = 9 for Mino. Soleus: n = 10 for Control, n = 9 for Mino. Values are mean ± SD.
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TABLE 3 | Table of descriptive statistical analysis summary for whole muscle parameters measured for A: EDL and B: Soleus.
A EDL
Parameter Difference between means 95% CI P-value N (Control, Mino)
Muscle mass (mg) −1.09 [−2.417, 0.2372] 0.102 (n = 10, n = 10)
Muscle length (mm) 0 [−0.2426, 0.2426] NS (n = 10, n = 10)
Max force (mN) −55.16 [−105.7, −4.632] 0.035 (n = 7, n = 9)
Specific force (mN/mm2) −7.264 [−62.29, 47.76] NS (n = 7, n = 9)
Half frequency (Hz) −2.128 [−8.287, 4.032] NS (n = 7, n = 9)
Hill coefficient (%) −0.0524 [−0.7213, 0.6166] NS (n = 7, n = 9)
Fatigue endpoint (%) −4.69 [−14.58, 5.2] NS (n = 7, n = 9)
Recovery endpoint (%) −1.236 [−6.53, 4.058] NS (n = 7, n = 9)
Time to peak (ms) 1.183 [−1.7929, 4.094] NS (n = 7, n = 9)
Half relaxation time (ms) 0.246 [−2.689, 3.181] NS (n = 7, n = 9)
Twitch absolute force (mN) 0.4314 [−8.272, 9.135] NS (n = 7, n = 9)
Twitch specific force (mN/mm2) 6.492 [−3.674, 16.66] NS (n = 7, n = 9)
B Soleus
Parameter Difference between means 95% CI P-value N (Control, Mino)
Muscle mass (mg) 0.1 [−1.478, 1.678] NS (n = 10, n = 10)
Muscle length (mm) − − NS (n = 10, n = 10)
Max force (mN) 13.89 [−14.46. 42.24] NS (n = 10, n = 9)
Specific force (mN/mm2) 13.35 [−24.9, 51.6] NS (n = 10, n = 9)
Half frequency (Hz) −1.205 [−2.715, 0.305] NS (n = 10, n = 9)
Hill coefficient (%) 0.237 [−0.3161, 0.7907] NS (n = 10, n = 9)
Fatigue endpoint (%) 2.244 [−5.317, 9.805] NS (n = 10, n = 9)
Recovery endpoint (%) 3.942 [−2.931, 10.82 NS (n = 10, n = 9)
Time to peak (ms) 10.11* [1.338, 18.88] 0.026 (n = 10, n = 9)
Half relaxation time (ms) 26.63* [1.822. 51.43] 0.037 (n = 10, n = 9)
Twitch absolute force (mN) 4.704 [−5.435, 14.84] NS (n = 10, n = 9)
Twitch specific force (mN/mm2) 5.149 [−6.567, 16.86] NS (n = 10, n = 9)
*P < 0.05. NS: not significant via unpaired t-test.
it was interesting to note (Figures 4E,F) that in the mice
minocycline treatment did not significantly alter the myosin
heavy chain content of the predominately fast-twitch TA muscles.
The downregulation of myosin heavy chain content with
minocycline is of importance in when considering atrophic
muscle diseases and conditions. In cancer cachexia-induced
muscle atrophy, there is a targeted reduction in myosin heavy
chain content in both cell culture and mouse models of cancer,
suggested to be linked to upregulation of ubiquitin proteasome
signalling (Ladner et al., 2003; Acharyya et al., 2004) while in
sarcopenia there is a preferential loss of fast-myosin (Larsson
et al., 2019). Our results did not investigate the degradation
pathways in response to minocycline, but given the decline in
protein synthesis we report in C2C12 myotubes, it is possible
that minocycline could reduce fast myosin heavy chain content
through such a mechanism. In the present study, mice studied
exhibited no abnormalities in body condition, posture and injury
were found following 5 days of injection. Upon sacrifice and
muscle removal, apart from the findings reported in this study
the muscles were healthy and could sustain and recover from
an extreme fatigue protocol. The C2C12 cells were monitored
for 2 days post treatment, it is possible that there could be
an apoptotic response post 2 days of minocycline treatment.
However, given mature C2C12 myotubes cannot be treated for
more than several days, it was not possible for us to properly test
this possibility.
Minocycline exudes its antibacterial function via supressing
protein synthesis of the prokaryotic 30S ribosome (Garrido-
Mesa et al., 2013). It is apparent from our findings that
minocycline can also supress protein synthesis through other
mechanisms in eukaryotic cells. Jung et al. (2014) reported that
minocycline reduced protein synthesis in minocycline treated
cancer cells, concomitant with both a reduction in mTOR
and p-P70S6K and increase in eIF2α phosphorylation; if this
signalling occurs in minocycline treated skeletal muscle, these
are potential mechanisms for the reduced protein synthesis
and myosin heavy chain content in minocycline treated C2C12
myotubes. It is also unknown whether the effects of minocycline
are common to other tetracyclines, or whether the findings of our
study were a unique effect of minocycline specifically. Indeed,
doxycycline treatment did not elicit a reduction in myosin
heavy chain content in C2C12 cultured myotubes, but instead
caused hypertrophy and increased myosin heavy chain content
(Obradović et al., 2016). However, Obradović et al. (2016)
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FIGURE 4 | Minocycline treatment (10 µg/mL) for 48 h decreases protein synthesis and myosin heavy chain abundance in cultured C2C12 myotubes. (A,B) Protein
synthesis was reduced by 23% with 48 h minocycline treatment (10 µg/mL), as measured via puromycin incorporation in C2C12 myotubes. (C,D) Myosin heavy
chain abundance was reduced with 48 h minocycline treatment (10 µg/mL) in C2C12 myotubes. (E,F) Myosin heavy chain abundance was unchanged between
minocycline treated TA muscles and untreated controls (n = 5 from each group). (G,H) Light microscope images (X20 magnification) of C2C12 myotubes treated with
minocycline. Scale bars have been included in the bottom right corner of images. n = 4 independent experiments for each unless specified. **p < 0.01, ***p < 0.001
via unpaired t-tests. Values are mean ± SD.
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provided doxycycline treatment prior to myotube differentiation,
suggesting doxycycline may have some positive effect on
myogenesis. Conversely, another study suggested tetracycline
(Sumycin) treatment impaired myotube formation in C2C12
cells (Hamai et al., 1997). Taken together, it is possible that
despite being in the same broad drug classification or category,
different forms of tetracyclines could elicit separate effects on
skeletal muscle differentiation and morphology. Indeed, our
study demonstrates that minocycline impairs protein synthesis
in formed myotubes, and that the effects of tetracyclines are not
limited to myotube formation and differentiation but also has a
fibre-type specific impact on the adult fast-twitch EDL muscle.
In conclusion, our findings show that minocycline treatment
produces mild adverse effects on absolute force production and
mass in fast-twitch EDL muscle as well as a reduction of protein
synthesis and myosin heavy chain content in C2C12 cultured
cells. These factors should be considered in future research
examining minocycline as a possible treatment for destructive
and wasting muscle conditions such as Duchenne muscular
dystrophy, cancer cachexia and sarcopenia.
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